biostudies-literatureKaraulic AConseil Général 06Fondation ARC pour la Recherche sur le CancerInstitut National du CancerAgence Nationale de la RechercheCancéropôle PACAInsermCentre National de la Recherche Scientifiquethe Région Provence-Alpes-Côte d'AzurUniverity Cote d'AzurEUR HEALTHY from the University Cote d'AzurLa Ligue Contre le Cancer3659https://www.ebi.ac.uk/biostudies/studies/S-EPMC12650705biostudies-literatureUnknown17(22)<h4>Background/objectives</h4>The advent of tyrosine kinase inhibitors (TKI), therapeutic antibodies and inducers of apoptosis has revolutionized cancer treatment, yet their application in pediatric tumors, particularly medulloblastoma, remains understudied. Understanding the expression of these targets in specific genetic subgroups could unveil potential repositioning opportunities for already approved drugs.<h4>Methods</h4>We analyzed RNA-sequencing data from the R2 Genomics Analysis and Visualization Platform (N = 763 patients, multiple cohorts) and the TCGA database (six individual cohorts 828 patients) to assess the expression of 73 potential targets of TKIs and antibodies targeting immune checkpoint inhibitors (ICI) or membrane receptors and inducers of apoptosis. These treatments, FCancersExploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment.PMC12650705no numberEquipe Labellisée 2022No numberNo NumberEquipe Labellisée 2019NO numberARCAGEING2023020006332Pages GKaraulic AFournier CfalseExploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment.<h4>Background/objectives</h4>The advent of tyrosine kinase inhibitors (TKI), therapeutic antibodies and inducers of apoptosis has revolutionized cancer treatment, yet their application in pediatric tumors, particularly medulloblastoma, remains understudied. Understanding the expression of these targets in specific genetic subgroups could unveil potential repositioning opportunities for already approved drugs.<h4>Methods</h4>We analyzed RNA-sequencing data from the R2 Genomics Analysis and Visualization Platform (N = 763 patients, multiple cohorts) and the TCGA database (six individual cohorts 828 patients) to assess the expression of 73 potential targets of TKIs and antibodies targeting immune checkpoint inhibitors (ICI) or membrane receptors and inducers of apoptosis. These treatments, F2025-01-01T00:00:00Z2025 Nov2026-07-06T03:18:38.377Z2026-07-06T03:11:16.555ZS-EPMC126507054130102410.3390/cancers17223659